CO2019011604A2 - Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos - Google Patents

Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos

Info

Publication number
CO2019011604A2
CO2019011604A2 CO2019011604A CO2019011604A CO2019011604A2 CO 2019011604 A2 CO2019011604 A2 CO 2019011604A2 CO 2019011604 A CO2019011604 A CO 2019011604A CO 2019011604 A CO2019011604 A CO 2019011604A CO 2019011604 A2 CO2019011604 A2 CO 2019011604A2
Authority
CO
Colombia
Prior art keywords
methods relating
compositions
compounds
inhibitor compounds
vmat2 inhibitor
Prior art date
Application number
CO2019011604A
Other languages
English (en)
Spanish (es)
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019011604(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CO2019011604A2 publication Critical patent/CO2019011604A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO2019011604A 2017-04-19 2019-10-18 Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos CO2019011604A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (1)

Publication Number Publication Date
CO2019011604A2 true CO2019011604A2 (es) 2019-10-31

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
CO2019011604A CO2019011604A2 (es) 2017-04-19 2019-10-18 Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos

Country Status (17)

Country Link
US (1) US11040970B2 (enExample)
EP (1) EP3612532B1 (enExample)
JP (1) JP7170662B2 (enExample)
KR (1) KR20190140968A (enExample)
CN (1) CN110770236B (enExample)
AU (1) AU2018254429A1 (enExample)
BR (1) BR112019021853A2 (enExample)
CA (1) CA3060251A1 (enExample)
CL (1) CL2019002919A1 (enExample)
CO (1) CO2019011604A2 (enExample)
ES (1) ES2971230T3 (enExample)
JO (1) JOP20190239A1 (enExample)
MA (1) MA50145A (enExample)
MX (1) MX2019012336A (enExample)
PE (1) PE20191784A1 (enExample)
TW (1) TW201841913A (enExample)
WO (1) WO2018195121A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090676A1 (ru) 2017-01-27 2021-10-08 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
IL273300B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
TW202011963A (zh) * 2018-06-14 2020-04-01 美商紐羅克里生物科學有限公司 Vmat2抑制劑化合物、組合物及其相關方法
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
DK4168409T3 (da) 2021-03-22 2025-06-02 Neurocrine Biosciences Inc Vmat2-inhibitorer og fremgangsmåder til brug
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
CA3229341A1 (en) 2021-08-20 2023-02-23 Ryan TERRY-LORENZO Methods of screening for vmat2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
WO2005000846A1 (en) 2003-06-20 2005-01-06 F.Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as dpp-iv inhibitors
US20060035883A1 (en) 2004-08-13 2006-02-16 Tedford Clark E Novel serotonin receptor ligands and their uses thereof
AU2007317242B2 (en) * 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9012471B2 (en) 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
ES2896678T3 (es) 2008-09-18 2022-02-25 Auspex Pharmaceuticals Inc Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
CN107438606B (zh) 2015-02-06 2020-09-18 纽罗克里生物科学有限公司 [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1

Also Published As

Publication number Publication date
AU2018254429A1 (en) 2019-11-07
US11040970B2 (en) 2021-06-22
CL2019002919A1 (es) 2020-01-17
ES2971230T3 (es) 2024-06-04
MX2019012336A (es) 2020-07-14
TW201841913A (zh) 2018-12-01
CA3060251A1 (en) 2018-10-25
EP3612532C0 (en) 2023-12-13
WO2018195121A1 (en) 2018-10-25
EP3612532A1 (en) 2020-02-26
JP2020517607A (ja) 2020-06-18
PE20191784A1 (es) 2019-12-24
JOP20190239A1 (ar) 2019-10-09
CN110770236A (zh) 2020-02-07
BR112019021853A2 (pt) 2020-05-26
CN110770236B (zh) 2023-03-24
US20200131173A1 (en) 2020-04-30
KR20190140968A (ko) 2019-12-20
JP7170662B2 (ja) 2022-11-14
EP3612532B1 (en) 2023-12-13
MA50145A (fr) 2020-07-29

Similar Documents

Publication Publication Date Title
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
MX2017010062A (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
ECSP109958A (es) Derivados de pirimidina 934
NI200900181A (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos.
CL2021000421A1 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende.
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
MX2017009824A (es) Triazoles sustituidos y metodos relacionados a estos.
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
CO2020016080A2 (es) Compuestos
PE20171348A1 (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
AR099071A1 (es) Antagonistas selectivos de nr2b
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CU20130065A7 (es) Derivados de indol